doses of glp 1 GLP1-RAs in Type Diabetes: Dosing and Pharmacokinetics | Diabettech Compounded GLP-1 Treatment

First described in the early 19th century, the pigment was initially thought to be melanin, but it was later found to be lipofuscin deposited in macrophages within the lamina propria as a result of apoptosis

Excessive consumption of this product may have laxative effects

Administration Injection type: Intramuscular (IM) or subcutaneous IM injection sites: Deltoid (upper arm), gluteus (buttock), or vastus lateralis (outer thigh) Subcutaneous sites: Abdomen, outer thigh, or back of upper arm Needle gauge: 25-27 gauge for IM, insulin syringe for subcutaneous Timing: Morning or early afternoon is preferred, as the energy boost may interfere with sleep if taken late in the day

Thats important, but a more important message is to treat our diabetic patients with this group of agents

Its the same logic we apply across our peptide protocols

What is defined and regulated is the color additive DHA, or dihydroxyacetone